Literature DB >> 25809744

Perfusion volume correlates, percentage of involution, and clinical efficacy at diverse follow-up survey times after MR-guided focused ultrasound surgery in uterine fibroids: first report in a Mexican mestizo population.

Ana Luz Carrasco-Choque1, Yeni Fernandez-de Lara, Ingrid Vivas-Bonilla, Cecilia Romero-Trejo, Antonio R Villa, Ernesto Roldan-Valadez.   

Abstract

OBJECTIVES: To evaluate the clinical efficacy of magnetic resonance-guided focused ultrasound surgery in a Mexican mestizo population.
METHODS: This retrospective study included 159 women (mean age 37 ± 6.4 years, range 22-53 years) from 2008 to 2010. Two hundred sixty-eight symptomatic uterine fibroids were treated using MR-guided focused ultrasound surgery. Parameters included initial perfused volume, final perfused volume, non-perfused volume (NPV), and treated volume ratio (TVR). Follow-up up to 15 months assessed treatment efficacy and symptomatic relief. Non-parametric statistics and the Kaplan-Meier method were performed.
RESULTS: T2-weighted hypointense fibroids showed a frequency of 93.6%; isointense and hyperintense fibroids had frequencies of 5.60 and 1.1%. There was a negative correlation between NPV and age (r = -0.083, p = 0.307) and treatment time (r = -0.253, p = 0.001). Median TVR was 96.0% in small fibroids and 76.5% in large fibroids. Involution of 50% and 80% was achieved at months 6-7 and month 11, respectively. Relief of symptoms was significant (p < 0.05).
CONCLUSIONS: Our data show that higher TVR attained immediately post-treatment of MRgFUS favours higher involution percentages at follow-up; however, careful patient selection and use of pretreatment imaging are important components for predicting success using MR-guided focused ultrasound surgery. KEY POINTS: • Type 1 fibroids were the most common (93.2%). • Age and treated volume were not correlated (r s   = -0.215, p = 0.165). • Small fibroids achieved a higher treated volume than large (96.0% vs. 76.5%). • A 50% involution was achieved at 6-month follow-up for type-1 fibroid. • A decrease of 80% was reached at 11 months for type-1 fibroids.

Entities:  

Mesh:

Year:  2015        PMID: 25809744     DOI: 10.1007/s00330-015-3707-2

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  32 in total

1.  Accuracy of magnetic resonance imaging and transvaginal ultrasonography in the diagnosis, mapping, and measurement of uterine myomas.

Authors:  Margit Dueholm; Erik Lundorf; Estrid S Hansen; Susanne Ledertoug; Frede Olesen
Journal:  Am J Obstet Gynecol       Date:  2002-03       Impact factor: 8.661

2.  MR-guided focus ultrasound (MRgFUS) for symptomatic uterine fibroids: predictors of treatment success.

Authors:  Ronit Machtinger; Yael Inbar; Shlomo Cohen-Eylon; Dahlia Admon; Aviva Alagem-Mizrachi; Jaron Rabinovici
Journal:  Hum Reprod       Date:  2012-09-26       Impact factor: 6.918

3.  Focused ultrasound surgery of intramural leiomyomas may facilitate fertility: a case report.

Authors:  Miriam M F Hanstede; Clare M C Tempany; Elizabeth A Stewart
Journal:  Fertil Steril       Date:  2007-02-08       Impact factor: 7.329

Review 4.  [Principles and technique of magnetic resonance guided focused ultrasound surgery (MRgFUS) in the treatment of uterine fibroids].

Authors:  Jorge Vázquez-Lamadrid; Yeni Fernández-de Lara; Analuz Carrasco-Choque; Cecilia Romero-Trejo; Juan Cosme-Labarthe; Ernesto Roldan-Valadez
Journal:  Gac Med Mex       Date:  2011 Jul-Aug       Impact factor: 0.302

5.  Magnetic resonance imaging-guided focused ultrasound surgery for symptomatic uterine fibroids: estimation of treatment efficacy using thermal dose calculations.

Authors:  Sang-Wook Yoon; Sun Hee Cha; Young Geon Ji; Hyun Cheol Kim; Mee Hwa Lee; Jin Ho Cho
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2013-03-22       Impact factor: 2.435

6.  Focused ultrasound treatment of uterine fibroid tumors: safety and feasibility of a noninvasive thermoablative technique.

Authors:  Elizabeth A Stewart; Wladyslaw M W Gedroyc; Clare M C Tempany; Bradley J Quade; Yael Inbar; Tilman Ehrenstein; Asher Shushan; Jonathan T Hindley; Robert D Goldin; Matthias David; Miri Sklair; Jaron Rabinovici
Journal:  Am J Obstet Gynecol       Date:  2003-07       Impact factor: 8.661

7.  Clinical improvement and shrinkage of uterine fibroids after thermal ablation by magnetic resonance-guided focused ultrasound surgery.

Authors:  J Rabinovici; Y Inbar; A Revel; Y Zalel; J M Gomori; Y Itzchak; E Schiff; S Yagel
Journal:  Ultrasound Obstet Gynecol       Date:  2007-10       Impact factor: 7.299

8.  Uterine leiomyomas: MR imaging-guided focused ultrasound surgery--results of different treatment protocols.

Authors:  Fiona M Fennessy; Clare M Tempany; Nathan J McDannold; Minna J So; Gina Hesley; Bobbie Gostout; Hyun S Kim; George A Holland; Dennis A Sarti; Kullervo Hynynen; Ferenc A Jolesz; Elizabeth A Stewart
Journal:  Radiology       Date:  2007-04-19       Impact factor: 11.105

9.  MRI guidance of focused ultrasound therapy of uterine fibroids: early results.

Authors:  Jonathan Hindley; Wladyslaw M Gedroyc; Lesley Regan; Elizabeth Stewart; Clare Tempany; Kullervo Hynyen; Kullervo Hynnen; Nathan Mcdannold; Nathan Macdanold; Yael Inbar; Yacov Itzchak; Jaron Rabinovici; Hyun S Kim; Kevin Kim; Jean-François Geschwind; Gina Hesley; Bobbie Gostout; Brian Gostout; Tillman Ehrenstein; Sylvia Hengst; Miri Sklair-Levy; Asher Shushan; Ferenc Jolesz
Journal:  AJR Am J Roentgenol       Date:  2004-12       Impact factor: 3.959

10.  Early evaluation of magnetic resonance imaging guided focused ultrasound sonication in the treatment of uterine fibroids.

Authors:  Y Himabindu; M Sriharibabu; Vinay Nyapathy; Anindita Mishra
Journal:  Indian J Med Res       Date:  2014-02       Impact factor: 2.375

View more
  1 in total

1.  Oxytocin Administration in High-Intensity Focused Ultrasound Treatment of Myomata.

Authors:  Tomasz Lozinski; Justyna Filipowska; Piotr Krol; Anna Kubaty; Piotr Wegrzyn
Journal:  Biomed Res Int       Date:  2018-07-02       Impact factor: 3.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.